SCHEMBL9945527

SCHEMBL9945527

CC(C)[Si]1(C(C)C)OC[C@H]2O[C@@H](n3cnc4c(NC(=O)c5ccccc5)ncnc43)[C@H](CO)C2O[Si](C(C)C)(C(C)C)O1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ P2RY12 Q9H244 1/20 0.41
▸ ADORA2A P29274 3/20 0.41
▸ ADORA2B P29275 2/20 0.41
▸ PRMT6 Q96LA8 1/20 0.41
▸ ADORA1 P30542 1/20 0.41
▸ PDE4A P27815 1/20 0.40
▸ PDE4B Q07343 1/20 0.40
▸ PDE4C Q08493 1/20 0.40
▸ PDE4D Q08499 1/20 0.40
▸ TP53 P04637 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ ALOX12 P18054 1/20 0.40
▸ NFKB1 P19838 1/20 0.40
▸ HIF1A Q16665 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ PMP22 Q01453 1/20 0.40
▸ ADORA3 P0DMS8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10459187 0.90 PDE4A (0.47) P2RY12ADORA2AADORA2BPDE4APDE4B
SCHEMBL3360473 0.90 PDE4A (0.47) P2RY12ADORA2AADORA2BPDE4APDE4B
SCHEMBL9945534 0.90 PDE4A (0.47) P2RY12ADORA2AADORA2BPDE4APDE4B
SCHEMBL29674419 0.90 PDE4A (0.47) P2RY12ADORA2AADORA2BPDE4APDE4B
SCHEMBL19509816 0.90 PDE4A (0.47) P2RY12ADORA2AADORA2BPDE4APDE4B
SCHEMBL22984018 0.90 PDE4A (0.47) P2RY12ADORA2AADORA2BPDE4APDE4B
SCHEMBL29772235 0.90 PDE4A (0.47) P2RY12ADORA2AADORA2BPDE4APDE4B
SCHEMBL19509705 0.90 PDE4A (0.47) P2RY12ADORA2AADORA2BPDE4APDE4B
SCHEMBL19509704 0.86 PRMT6 (0.42) P2RY12ADORA2AADORA2BPRMT6PDE4A
SCHEMBL19500434 0.86 PRMT6 (0.42) P2RY12ADORA2AADORA2BPRMT6PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149888-A1 SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUCTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS CHEMGENES CORPORATION 2012-06-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149888-A1 SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUCTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS TYMP, MTAP, GART P2RY12 512/4885ADORA2A 170/4885ADORA2B 236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback